Reply

Arthritis Care and Research

Volumn 63, Issue 9, 2011, Pages 1355-

  Beukelman, Timothy ^a   Cron, Randy Q ^a   Patkar, Nivedita M ^a   Saag, Kenneth G ^a   Dewitt, Esi Morgan ^b   Lovell, Daniel J ^b   Ilowite, Norman T ^c   Kimura, Yukiko ^d   Laxer, Ronald M ^e   Martini, Alberto ^f   Ruperto, Nicolino ^f   Rabinovich, C Egla ^g  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f G GASLINI INSTITUTE   (Italy)

^g DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALGORITHM; CATARACT; CUSHING SYNDROME; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPOPROTEINEMIA; GLAUCOMA; GROWTH INHIBITION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LETTER; LONG TERM CARE; OSTEOPOROSIS; PROGNOSIS; PUBLICATION; SYNOVITIS; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 80052289849     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20520     Document Type: Letter

References (10)

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84. (Pubitemid 351847559)
2. Van Tuyl LH, Lems WF, Voskuyl AE, Dijkmans BA, Boers M, Kerstens PJ,. Inclusion of glucocorticoids in recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: comment on the article by Saag et al [letter]. Arthritis Rheum 2009; 61: 141-2.
3. Saag KG, Furst DE,. Reply [letter]. Arthritis Rheum 2009; 61: 142.
4. Rosenberg AM, Oen KG,. Polyarthritis. In:, Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 249-61.
5. Ilowite NT, Laxer RM,. Pharmacology and drug therapy. In:, Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 71-126.
6. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-9. (Pubitemid 30151920)
7. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.
8. Cush JJ,. Early rheumatoid arthritis: is there a window of opportunity? J Rheumatol Suppl 2007; 80: 1-7. (Pubitemid 350076862)
9. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L,. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 1986; 314: 1269-76. (Pubitemid 16101390)
10. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-201. (Pubitemid 38924397)